April 2, 2020

NIDA director outlines potential risks to people who smoke and use drugs during COVID-19 pandemic

The precarious intersection of the COVID-19 national health emergency and the concurrent epidemic of drug overdose deaths is outlined in the Annals of Internal Medicine this week by Dr. Nora D. Volkow, director of the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health. Dr. Volkow discusses how the serious health risks of COVID-19 pose unique challenges to people who smoke or vape, are already struggling with substance use disorders (SUD), or are in recovery from addiction.

People recovering from addiction now face new challenges. Physical distancing measures, while critical to COVID-19 mitigation, eliminate the important element of social support needed for addiction recovery. Additionally, people with opioid use disorder may face barriers to obtaining medications (i.e., buprenorphine or methadone) or obtaining services from syringe services programs. Social distancing will also decrease the likelihood of observed overdoses; administration of naloxone to reverse overdose may be less likely, potentially resulting in more fatalities.

> Read the announcement

NIDA. (2020, April 2). NIDA Director outlines potential risks to people who smoke and use drugs during COVID-19 pandemic. Retrieved from https://www.drugabuse.gov/news-events/news-releases/2020/04/nida-director-outlines-potential-risks-to-people-who-smoke-use-drugs-during-covid-19-pandemic on 2020, April 2

Getting Help